CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
CDK12 mutation
|
Ovarian Cancer
|
CDK12 mutation
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
CDK12 mutation
|
HER2 Negative Breast Cancer
|
CDK12 mutation
|
HER2 Negative Breast Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
AST-2970 Resistant: C3 – Early Trials
|
AST-2970 Resistant: C3 – Early Trials
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
enzalutamide capsule Resistant: C3 – Early Trials
|
enzalutamide capsule Resistant: C3 – Early Trials
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
rucaparib Resistant: C3 – Early Trials
|
rucaparib Resistant: C3 – Early Trials
|
CDK12 mutation
|
Breast Cancer
|
CDK12 mutation
|
Breast Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
GnRH stimulant Resistant: C3 – Early Trials
|
GnRH stimulant Resistant: C3 – Early Trials
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
enzalutamide capsule + abiraterone acetate Resistant: C3 – Early Trials
|
enzalutamide capsule + abiraterone acetate Resistant: C3 – Early Trials
|
CDK12 mutation
|
Ovarian Cancer
|
CDK12 mutation
|
Ovarian Cancer
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
CDK12 mutation
|
NSCLC
|
CDK12 mutation
|
NSCLC
|
olaparib Sensitive: C4 – Case Studies
|
olaparib Sensitive: C4 – Case Studies
|
CDK12 mutation
|
Prostate Cancer
|
CDK12 mutation
|
Prostate Cancer
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|